Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Pfizer Inc.’s $16 billion acquisition of Hospira, Inc. would likely be anticompetitive.
Under the order, first announced in August 2015, the companies are required to divest Pfizer’s generic acetylcysteine inhalation solution, and Hospira’s clindamycin phosphate, voriconazole, and melphalan hydrochloride injection products.
The Commission vote approving the final order was 4-0. (FTC File No. 151 0074; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085)
The FTC’s Bureau of Competition works with the Bureau of Economics to investigate alleged anticompetitive business practices and, when appropriate, recommends that the Commission take law enforcement action. To inform the Bureau about particular business practices, call 202-326-3300, send an e-mail to [email protected], or write to the Office of Policy and Coordination, Bureau of Competition, Federal Trade Commission, 600 Pennsylvania Ave., NW, Room CC-5422, Washington, DC 20580. To learn more about the Bureau of Competition, read Competition Counts. Like the FTC on Facebook, follow us on Twitter, and subscribe to press releases for the latest FTC news and resources.